I am a board-certified pediatric hematologic oncologist who specializes in bone marrow transplantation. I am also the Medical Director of Memorial Sloan Kettering’s Pediatric Day Hospital, a state-of-the-art facility where we provide the majority of treatment for children and young adults with cancer in a bright, uplifting setting.
Bone marrow transplantation brings together science and human medicine in an intellectually stimulating way. I educate parents of our patients about the options we can offer their children and advise them on the plan of therapy that we feel is best. It is one of the few fields of medicine where you get so close to the patient and his or her family, and are able to give so much of yourself as a physician.
In my research, I am seeking new therapies that are more effective while causing fewer side effects. One of my main research interests is new treatments for children with leukemia. I have developed several approaches for bone marrow transplantation that do not require total body irradiation (an approach used to destroy diseased bone marrow) and instead rely only on chemotherapy.
Memorial Sloan Kettering is a center of excellence for the care of children with bone marrow failure syndromes and low blood cell counts. I have developed a program for the diagnosis and management of these disorders and collaborate with other MSKCC based investigators and scientists at The Rockefeller University and NewYork-Presbyterian Hospital to research new approaches for these rare disorders.
Doctors at Memorial Sloan Kettering are among the most experienced in the country in the use of bone marrow transplants to treat children with thalassemia and sickle cell disease. We are establishing ourselves as a leading center for the treatment of these diseases, attracting patients from all over the world. I am investigating new ways to manage these diseases, including clinical research evaluating gene therapy.
Hearing that your child has cancer is one of the worst things anyone can experience. I have decided to give everything I can to children with cancer and their families to help them travel through this journey with compassion and good cheer. My greatest joy comes from seeing my patients smile and hearing their laughter. I find it enormously gratifying to see us achieving better and better survival rates, which means that more patients are growing up to live productive lives. In fact, one of the my greatest sources of satisfaction is attending the wedding of one of my patients.
- Clinical Expertise: Pediatric Oncology; Allogeneic and Autologous Bone Marrow and Peripheral Blood Stem Cell Transplantation; Congenital and Acquired Diseases of Hematopoiesis and Immunity
- Languages Spoken: English; Arabic; French
- Education: MD, Free University of Brussels (Belgium)
- Residencies: Metropolitan Hospital Center/New York Medical College
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Pediatrics; Pediatric Hematology-Oncology
Small TN, Papadopoulos EB, Boulad F, et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999; 93 :467
Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91 :1083
Boulad F, Steinherz P, Reyes B, et al. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. J Clin Oncol 1999; 17 :197
Castro-Malaspina H, Childs B, Laver J, et al. Hyperfractionated total lymphoid irradiation and cyclophosphamide for preparation of previously transfused patients undergoing HLA-identical marrow transplantation for severe aplastic anemia. Int J Radiat Oncol Biol Phys 1994; 29 :847
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Co-Investigated by Farid Boulad
- A Phase I Study of WT1-Sensitized T cells for Residual or Relapsed Leukemia after Allogeneic Hematopoietic Progenitor Cell Transplantation
- A Phase III Study of Remestemcel-L for Children with Acute Graft-versus-Host Disease that Persists Despite Steroids
- Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLA-Compatible Donor
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more